Ibogaine has real physiological risk. The contraindications are not a legal disclaimer — they are the specific conditions that have caused fatalities when missed. Before considering ceremony, understand which of these apply to you: cardiac arrhythmia or QT prolongation, SSRIs or SNRIs without a supervised taper, MAOIs, lithium or antipsychotics, methadone or suboxone without a transition protocol, severe liver or kidney disease, active psychosis or schizophrenia, and pregnancy.
Ibogaine contraindications fall into two categories: absolute (ceremony is not safe regardless of circumstances) and conditional (ceremony requires specific preparation first). The distinction matters. SSRIs are the most common contraindication we encounter — and they are conditional, not absolute. Cardiac arrhythmia is absolute. These are not the same kind of disqualifier.
Cardiac Contraindications — The Non-Negotiable
Ibogaine prolongs the QT interval — the period during which the heart resets between beats. In a person with pre-existing QT prolongation, a significant cardiac arrhythmia, or a recent myocardial infarction, this effect can trigger ventricular arrhythmia. This is the most common mechanism of ibogaine-related death.
An EKG is required before every iboga ceremony. Not as a formality — as the specific test that identifies this risk before it becomes a problem during the 12–24 hour experience. Any provider offering ibogaine without a pre-ceremony EKG is not operating safely. This is not a professional disagreement about best practice — it is a factual observation about ibogaine's specific mechanism of cardiac risk.
Absolute cardiac contraindications
- QT prolongation (QTc > 450ms warrants evaluation; QTc > 500ms is a hard stop)
- Significant cardiac arrhythmia
- Recent myocardial infarction
- Uncontrolled hypertension
- Structural heart disease — assessed case by case
People with a clean EKG, no cardiac history, and no QT-prolonging medications can proceed through screening. Cardiac monitoring is in place throughout ceremony.
SSRIs and SNRIs — Conditional, Not Absolute
SSRIs and SNRIs are the contraindication we encounter most often — not because they are the most dangerous in combination with ibogaine, but because they are the most common medications people are taking when they come to us.
The risk is serotonin syndrome: an overstimulation of serotonin receptors that, in severe cases, is fatal. Ibogaine affects serotonin receptor activity. Combining it with SSRIs or SNRIs without a washout period creates real risk.
This is not a permanent disqualifier. A supervised taper — completed under physician oversight — removes the risk. The timeline depends on the specific medication. Fluoxetine (Prozac), with its long half-life, requires a longer washout than sertraline (Zoloft) or escitalopram (Lexapro). Typical washout periods range from two to six weeks, but the prescribing physician sets the timeline — not the ceremony provider.
If you are currently on an SSRI or SNRI and want to pursue ceremony, the path involves working with your doctor to taper safely and waiting for adequate washout before proceeding. This requires time and medical involvement. It does not require abandoning the intention.
MAOIs — Absolute
Monoamine oxidase inhibitors (MAOIs) are an absolute contraindication. The combination of MAOIs with ibogaine carries a severe risk of serotonin syndrome. There is no safe protocol, no adequate washout period that resolves the interaction, and no exception.
Prescribed MAOIs include phenelzine (Nardil), tranylcypromine (Parnate), and isocarboxazid (Marplan). Some people are on MAOIs for treatment-resistant depression — one of the same conditions ibogaine is sought for. If that describes your situation, ibogaine is not accessible while you remain on these medications, and transitioning away from MAOIs is its own careful medical process.
Lithium and Antipsychotics — Absolute
Lithium and most antipsychotics are absolute contraindications. The combination with ibogaine produces interactions that are both unpredictable and potentially dangerous. Several antipsychotics also prolong the QT interval independently, compounding the cardiac risk.
People taking lithium for mood stabilization or antipsychotics for bipolar disorder or schizophrenia are not appropriate candidates for ibogaine ceremony. This overlaps with the psychiatric contraindications below — if someone requires antipsychotic medication for stability, the underlying condition is also a contraindication.
Methadone and Suboxone — Transition Protocol Required
Methadone and buprenorphine (suboxone) are not automatic disqualifiers. People seeking ibogaine for opioid addiction are often on these medications, and some of the most committed candidates we speak with are in this situation. But the transition required is more involved than an SSRI taper.
Methadone has a long and variable half-life, significant cardiac effects including QT prolongation at higher doses, and a complex interaction profile with ibogaine. The standard approach is a supervised transition from methadone to a shorter-acting opioid — typically morphine or oxycodone — followed by a period of abstinence before ceremony. This takes weeks and requires physician oversight throughout.
Suboxone (buprenorphine/naloxone) presents a different challenge: buprenorphine binds opioid receptors with very high affinity, which can interfere with ibogaine's effects on those receptor systems. A transition protocol is required here as well, managed by a physician familiar with ibogaine treatment.
If you are on methadone or suboxone and want to pursue ibogaine ceremony, it is possible — but the preparation timeline is measured in months, not weeks.
Liver and Kidney Disease
Ibogaine is metabolised primarily by the liver via the enzyme CYP2D6. In a person with severe hepatic impairment, clearance is reduced — ibogaine and its active metabolite noribogaine accumulate to higher levels and persist longer, amplifying both therapeutic and adverse effects. The cardiac risk increases accordingly.
Severe liver or kidney disease is an absolute contraindication. Mild or managed conditions — a history of hepatitis, early fibrosis, a single elevated enzyme reading — are evaluated case by case. A blood panel including liver function tests (ALT, AST, bilirubin) and kidney function markers (creatinine, estimated GFR) is required as part of standard pre-ceremony screening.
People with a history of heavy alcohol use — a common population seeking ibogaine for addiction — should expect liver function to be evaluated carefully during intake.
Psychosis and Schizophrenia
Active psychosis and schizophrenia spectrum disorders are absolute contraindications for ibogaine and 5-MeO-DMT. Both medicines can destabilise psychotic conditions significantly — and the destabilisation is not reliably reversible. This is not a risk that preparation, dosing, or setting can adequately mitigate.
A personal history of a single psychotic episode in someone who has been stable for an extended period requires careful evaluation. It is not an automatic disqualifier, but it requires a thorough psychiatric assessment before any decision. Current stability does not eliminate the risk.
Family history of psychosis without any personal history is not a contraindication — but it is disclosed during screening and factored into the assessment.
The Stanford study published in Nature Medicine that documented 88% reductions in PTSD symptoms and 87% in depression symptoms at one month post-treatment included 30 special operations veterans — a population carefully screened to exclude psychotic conditions. The results do not apply to people who were excluded from that screening.
Pregnancy
Pregnancy is an absolute contraindication for ibogaine and 5-MeO-DMT. There is no protocol, circumstance, or preparation that changes this. Breastfeeding is also a contraindication.
Check your situation
If you want to check your own situation against these criteria before applying, the candidate screening tool walks through each contraindication individually. It takes about two minutes and gives a direct assessment based on your answers.
Who This Is Not For
Some of the most difficult conversations in this work are the ones that end in no.
A person arrives — often after years of treatment that has not worked, often carrying significant suffering — and the screening process identifies something that makes ceremony unsafe. A cardiac finding that never produced symptoms. A medication whose risks are not negotiable. A level of psychiatric instability that requires a different kind of support first.
The conversation that ends with "this is not the right path for you at this moment" is not a comfortable one. People who have found a thread of hope do not receive a no easily. Saying it directly, without softening it, is what responsible facilitation looks like.
Beyond the medical contraindications, ibogaine is also not appropriate for:
- People currently in acute psychiatric crisis or active suicidal ideation
- People seeking a shortcut — if the goal is to avoid the work of sustained change, the experience will disappoint
- People who cannot commit to preparation and integration — the 12–24 hour ceremony is one part of a longer process
- People who cannot access adequate medical supervision before and during ceremony
The Stanford study that changed how institutional medicine regards ibogaine examined a specific population: 30 veterans with PTSD, traumatic brain injury, and treatment-resistant conditions, all of whom passed rigorous screening. The outcomes — 88% reduction in PTSD symptoms, 87% in depression, 81% in anxiety at one month — came from people who were appropriate candidates. They are not predictive for people who were not.
Is This Right for You?
The contraindications above are what we screen for at the start of every intake conversation. Most people who apply do not have them — or have conditional factors (like SSRIs) that are manageable with preparation.
If you are uncertain, the first step is to understand your own situation honestly: current medications, any cardiac history, any psychiatric history, and whether you are in a stable enough place to hold what the experience produces. The candidate screening tool walks through this in about two minutes. For more detail on each contraindication, the FAQ covers the most common questions.
For people seeking ibogaine specifically for PTSD, the PTSD condition page covers the mechanism and evidence in detail. For opioid addiction, there is a specific protocol involved beyond the standard contraindication review — the ceremony page outlines what the screening process involves.
If your situation looks clear, the next step is to submit an application. We review every application personally and respond within 2–3 business days if your situation seems appropriate for a further conversation.
Sources: Stanford / Nature Medicine (2023) · PubMed / NCBI — ibogaine cardiac safety · Health Canada — controlled substances